5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 5 of 5 clinical reviews.
A clinical deep-dive into how pioglitazone performs differently in East Asian patients, covering CYP2C19/CYP2D6 pharmacogenomics, ethnicity-stratified trial subgroup data, lower BMI thresholds, and dosing considerations reviewed by the HealthRX.com medical team.
Evidence-based guide to pioglitazone dose adjustments for East Asian patients, covering CYP2C8 metabolism, lower BMI thresholds, fracture risk, and pharmacogenomic considerations.
Evidence-based review of pioglitazone pharmacogenomic and safety differences in East Asian populations, including dosing considerations, fracture risk, bladder cancer signals, and CYP2C8 metabolism variations.
Evidence-based review of how pioglitazone (Actos) performs in Black and African ancestry populations, including pharmacogenomic differences, dosing considerations, and clinical trial subgroup data.
Evidence-based review of how pioglitazone performs in Hispanic and Latino populations, covering pharmacogenomic variants, insulin resistance phenotypes, ethnicity-stratified trial data, and clinical dosing guidance.